BioSpace News Archive

As we ring in the new year and bid farewell to 2020, we continue to track a range of epidemiological indicators to monitor COVID-19 activity and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

MedX Health Corp. (TSXV:MDX)(“MedX” or “the Company”), a global leader in teledermatology, will be presenting at the SNN Network Canada Virtual Event on Thursday, January 7th at 5:00 PM EST. Mike Druhan, President of Dermatology Products & Services, will host the presentation and answer investors’ questions.

Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on December 30, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 38,250 shares, and restricted stock units for an aggregate of 35,100 s

Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced that it has completed its acquisition of Deloitte’s life sciences pricing and contracting solutions business and underlying technology. With the acquisition, Model N has broadened its portfolio to better serve life sciences companies

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer Lloyd Segal, Execu

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company’s common stock will begin trading on a split-ad

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 50,000 shares of Calithera’s common stock, at a per share exercise price of $4.91, the closing trading price on December 31, 2020.

Core One Labs Inc. is pleased to announce that, further to its press release of December 24, 2020, it has completed the acquisition of all of the outstanding share capital of Vocan Biotechnologies Inc. effective December 31, 2020.

Biocept, Inc., a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announced that it has granted inducement stock options to purchase an aggregate of 83,120 shares of its common stock to 14 new employees.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 11 individuals hired by Sarepta in December 2020.